A detailed history of Ubs Group Ag transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 47,762 shares of AXSM stock, worth $4.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,762
Previous 39,704 20.3%
Holding current value
$4.33 Million
Previous $3.2 Million 34.26%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$78.93 - $95.84 $636,017 - $772,278
8,058 Added 20.3%
47,762 $4.29 Million
Q2 2024

Aug 13, 2024

SELL
$65.72 - $80.5 $1.42 Million - $1.74 Million
-21,616 Reduced 35.25%
39,704 $3.2 Million
Q1 2024

May 13, 2024

BUY
$69.39 - $97.64 $1.47 Million - $2.07 Million
21,195 Added 52.82%
61,320 $4.89 Million
Q4 2023

Feb 09, 2024

BUY
$57.42 - $83.61 $421,520 - $613,781
7,341 Added 22.39%
40,125 $3.19 Million
Q3 2023

Nov 09, 2023

BUY
$69.25 - $82.21 $1.26 Million - $1.5 Million
18,205 Added 124.87%
32,784 $2.29 Million
Q2 2023

Aug 11, 2023

SELL
$58.41 - $90.35 $98,829 - $152,872
-1,692 Reduced 10.4%
14,579 $1.05 Million
Q1 2023

May 12, 2023

BUY
$58.39 - $75.0 $187,665 - $241,050
3,214 Added 24.62%
16,271 $1 Million
Q4 2022

Feb 08, 2023

SELL
$39.94 - $79.72 $209,445 - $418,051
-5,244 Reduced 28.65%
13,057 $1.01 Million
Q3 2022

Nov 10, 2022

BUY
$36.06 - $69.85 $141,138 - $273,392
3,914 Added 27.21%
18,301 $817,000
Q2 2022

Aug 10, 2022

SELL
$21.74 - $46.75 $43,566 - $93,687
-2,004 Reduced 12.23%
14,387 $551,000
Q1 2022

May 16, 2022

BUY
$23.7 - $41.39 $316,560 - $552,846
13,357 Added 440.24%
16,391 $678,000
Q4 2021

Feb 14, 2022

SELL
$30.7 - $43.36 $193,778 - $273,688
-6,312 Reduced 67.54%
3,034 $114,000
Q3 2021

Nov 15, 2021

SELL
$19.91 - $68.26 $36,554 - $125,325
-1,836 Reduced 16.42%
9,346 $308,000
Q2 2021

Aug 13, 2021

BUY
$50.63 - $73.5 $87,994 - $127,743
1,738 Added 18.4%
11,182 $754,000
Q1 2021

May 12, 2021

BUY
$55.91 - $81.44 $29,632 - $43,163
530 Added 5.95%
9,444 $535,000
Q4 2020

Feb 11, 2021

SELL
$66.31 - $86.52 $300,981 - $392,714
-4,539 Reduced 33.74%
8,914 $726,000
Q3 2020

Nov 12, 2020

SELL
$68.34 - $85.84 $253,678 - $318,638
-3,712 Reduced 21.63%
13,453 $959,000
Q2 2020

Jul 31, 2020

SELL
$49.87 - $98.69 $189,107 - $374,232
-3,792 Reduced 18.09%
17,165 $1.41 Million
Q1 2020

May 01, 2020

SELL
$41.2 - $101.31 $966,675 - $2.38 Million
-23,463 Reduced 52.82%
20,957 $1.23 Million
Q4 2019

Feb 14, 2020

SELL
$16.71 - $106.24 $22,090 - $140,449
-1,322 Reduced 2.89%
44,420 $4.59 Million
Q3 2019

Nov 14, 2019

BUY
$20.24 - $29.16 $857,710 - $1.24 Million
42,377 Added 1259.35%
45,742 $926,000
Q2 2019

Aug 14, 2019

BUY
$13.46 - $25.75 $20,593 - $39,397
1,530 Added 83.38%
3,365 $86,000
Q1 2019

May 14, 2019

BUY
$2.63 - $16.34 $4,826 - $29,983
1,835 New
1,835 $26,000
Q3 2018

Nov 14, 2018

SELL
$2.3 - $3.55 $641 - $990
-279 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$2.15 - $3.6 $599 - $1,004
279 New
279 $1,000
Q4 2017

Feb 14, 2018

SELL
$4.45 - $6.2 $1,068 - $1,488
-240 Closed
0 $0
Q3 2017

Nov 14, 2017

SELL
$4.65 - $6.1 $5,310 - $6,966
-1,142 Reduced 82.63%
240 $1,000
Q2 2017

Aug 14, 2017

BUY
N/A
1,113 Added 413.75%
1,382 $8,000
Q1 2017

Nov 14, 2017

BUY
N/A
269
269 $1,000

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $3.89B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.